Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/BCMA CAR-T for Refractory/Moderate-to-severe SLE
NCT06349343Phase 1Recruiting
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in systemic lupus erythematosus (SLE). Primary endpoint: Safety and tolerability at 1 year. Started Feb 2025; status: recruiting.
02
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06349343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349343.